SpringWorks Therapeutics gets breakthrough therapy designation for nirogacestat to treat desmoid tumours

This article was originally published here

The Breakthrough Therapy Designation was based on Phase 1 and Phase 2 data evaluating nirogacestat as a monotherapy in patients with desmoid tumors. Desmoid tumors are rare and

The post SpringWorks Therapeutics gets breakthrough therapy designation for nirogacestat to treat desmoid tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply